A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

2021210 citationsJournal Articlebronze Open Access

Authors

Detlef Schuppan · Johannes Gutenberg University Mainz

Markku Mäki · Johannes Gutenberg University Mainz

Knut E. A. Lundin · Oslo University Hospital

Jorma Isola · Tampere University

Tina Friesing-Sosnik · Johannes Gutenberg University Mainz

Juha Taavela · Tampere University

Alina Popp

Abstract

In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30.).

Topics & Keywords

Celiac Disease Research and Management Microscopic Colitis Helicobacter pylori-related gastroenterology studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 1, pp. 35-45

DOI: 10.1056/nejmoa2032441

Field-Weighted Citation Impact: 24.21